Patient Guide: A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS

Why Use Quri.ai for This Trial?

  • ✓ Simplified eligibility checker - know if you qualify in minutes
  • ✓ Direct contact with study coordinators at 105 locations
  • ✓ Plain language explanations of medical terms and procedures
  • ✓ Personalized enrollment support throughout your journey
  • ✓ Free service - no hidden fees or obligations
Trial ID: NCTNCT06008093
Status: 🟢 Enrolling Now
Condition: Carcinoma, Non-Small-Cell Lung
Phase: PHASE3

Where You Can Participate

This study is available at 105 locations across the country.

Top locations include:
  • • Birmingham, Alabama
  • • Anchorage, Alaska
  • • Chandler, Arizona
  • • And 102 more locations

Loading interactive enrollment tools...

The full interactive experience will load momentarily

A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS - Join Clinical Trial NCTNCT06008093

How to Join This Clinical Trial - NCTNCT06008093

Learn how to participate in this PHASE3 trial studying an investigational therapy for Carcinoma, Non-Small-Cell Lung. This study is currently enrolling participants.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with Carcinoma, Non-Small-Cell Lung. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
Carcinoma, Non-Small-Cell Lung
Treatment Being Tested
Investigational treatment
Study Phase
PHASE3 - Large-scale efficacy study
Enrollment Status
Currently enrolling participants
Study Identifier
NCTNCT06008093 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 105 locations. Find a study site near you:

Clinical Research Site

Birmingham, Alabama 35233 - United States

Status: WITHDRAWN

Clinical Research Site

Anchorage, Alaska 99508 - United States

Status: RECRUITING

Clinical Research Site

Chandler, Arizona 85224 - United States

Status: WITHDRAWN

Clinical Research Site

Tucson, Arizona 85724 - United States

Status: RECRUITING

Clinical Research Site

Irvine, California 92618 - United States

Status: RECRUITING

Clinical Research Site

La Jolla, California 92093 - United States

Status: RECRUITING

Clinical Research Site

Loma Linda, California 92357 - United States

Status: RECRUITING

Clinical Research Site

Los Alamitos, California 90720 - United States

Status: RECRUITING

Clinical Research Site

Los Angeles, California 90034 - United States

Status: RECRUITING

Clinical Research Site

Los Angeles, California 90095 - United States

Status: WITHDRAWN

And 95 more locations available. Contact us to find the nearest participating site.

How to Enroll in This Study

To learn more about participating in this PHASE3 clinical trial for Carcinoma, Non-Small-Cell Lung:

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

  • Discover clinical trials before competitors
  • Access exclusive contact information
  • Track sponsor pipelines and opportunities
  • Connect with decision makers directly
  • Win more business partnerships